phrykt

Vertex Pharmaceuticals Inc / Ma (VRTX): who owns it and who trades it

As of Nov 16, 2026, VRTX insiders reported 90 open-market sales worth $140M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jeffrey M Leiden (Chair), with $28.7M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Vertex Pharmaceuticals Inc / Ma

From the latest filings

Overall: about as much buying as selling. Congress mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns VRTX

1,745 funds and institutions reported VRTX shares worth $120B at the end of Q2 2026, about 95% of the company. The largest holder is Capital World Investors with 10.3%.

Funds and institutions (13F) 95%Everyone else 5%

10 largest owners, by share of the company

Capital World Investors10.3%
BlackRock, Inc.9.5%
Capital Research Global Investors7.7%
Vanguard Capital Management LLC6.5%
State Street Corp4.7%
Invesco Ltd.3.2%
JPMorgan Chase & Co2.6%
Geode Capital Management, LLC2.4%
Vanguard Portfolio Management LLC1.9%
Capital International Investors1.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Capital World Investors26.12M10.29%$13B+3%
BlackRock, Inc.24.11M9.50%$12B+1%
Capital Research Global Investors19.49M7.68%$9.7B-8%
Vanguard Capital Management LLC16.58M6.53%$8.2B+0%
State Street Corp11.87M4.68%$5.9B+1%
Invesco Ltd.8.04M3.17%$4B+214%
JPMorgan Chase & Co6.52M2.57%$3.3B–
Geode Capital Management, LLC6.02M2.37%$3B-2%
Vanguard Portfolio Management LLC4.88M1.92%$2.4B-5%
Capital International Investors4.70M1.85%$2.3B-8%
Loomis Sayles & Co L P3.92M1.54%$1.9B-2%
Franklin Resources Inc3.35M1.32%$1.7B+507%
Wellington Management Group LLP3.25M1.28%$1.6B+1%
Morgan Stanley3.24M1.28%$1.6B+2%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC3.09M1.22%$1.5B+1%
Bank of America Corp3.04M1.20%$1.5B+6%
Alliancebernstein L.P.3.02M1.19%$1.3B-23%
Jennison Associates LLC3.00M1.18%$1.5B+9%
Norges Bank2.97M1.17%$1.5B–
Ameriprise Financial Inc2.60M1.03%$1.3B-1%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, VRTX insiders reported $0 of open-market purchases and $140M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$140M
90 trades, 13 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Nov 12, 2026
Filed Nov 16, 2026

Purchases and sales by month

$64.4M$64.4MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 12, 2026Charles F Wagner JrVice presidentSale plan15,286$547.87$8.4MForm 4
Nov 6, 2026Reshma KewalramaniCEOSale plan11,866$531.53$6.3MForm 4
Jul 2, 2026Ourania TatsisVice presidentSale plan1,500$524.99$787KForm 4
Jul 2, 2026Duncan McKechnieVice presidentSale plan1,541$519.00$800KForm 4
Jul 1, 2026Joy LiuVice presidentSale plan828$502.71$416KForm 4
Jun 26, 2026Carmen BozicVice presidentSale plan596$482.50$288KForm 4
Jun 18, 2026Carmen BozicVice presidentSale plan1,020$462.17$471KForm 4
Jun 15, 2026Carmen BozicVice presidentSale plan4,062$450.00$1.8MForm 4
Jun 5, 2026Carmen BozicVice presidentSale plan1,745$450.00$785KForm 4
Jun 1, 2026Joy LiuVice presidentSale plan828$439.91$364KForm 4
May 29, 2026Carmen BozicVice presidentSale plan1,974$450.00$888KForm 4
May 15, 2026Mark E. BunnageVice presidentSale plan33$453.45$15KForm 4
May 15, 2026Carmen BozicVice presidentSale plan1,354$453.45$614KForm 4
May 12, 2026Carmen BozicVice presidentSale plan6,988$450.00$3.1MForm 4
May 4, 2026Sangeeta N. BhatiaDirectorSale plan318$423.73$135KForm 4
May 1, 2026Joy LiuVice presidentSale plan1,104$425.02$469KForm 4
Apr 1, 2026Joy LiuVice presidentSale plan978$449.17$439KForm 4
Mar 27, 2026Carmen BozicVice presidentSale plan2,329$450.95$1.1MForm 4
Mar 13, 2026Carmen BozicVice presidentSale plan2,329$481.79$1.1MForm 4
Mar 11, 2026Duncan McKechnieVice presidentSale plan2,633$498.42$1.3MForm 4
Mar 4, 2026Duncan McKechnieVice presidentSale plan2,437$475.30$1.2MForm 4
Mar 2, 2026Joy LiuVice presidentSale plan892$495.96$442KForm 4
Feb 27, 2026Reshma KewalramaniCEOSale plan3,278$488.27$1.6MForm 4
Feb 27, 2026Reshma KewalramaniCEOSale plan2,510$487.13$1.2MForm 4
Feb 27, 2026Reshma KewalramaniCEOSale plan240$482.84$116KForm 4
Feb 27, 2026Reshma KewalramaniCEOSale plan120$481.50$57.8KForm 4
Feb 27, 2026Reshma KewalramaniCEOSale plan400$479.75$192KForm 4
Feb 27, 2026Reshma KewalramaniCEOSale plan460$489.32$225KForm 4
Feb 27, 2026Reshma KewalramaniCEOSale plan1,725$496.95$857KForm 4
Feb 27, 2026Reshma KewalramaniCEOSale plan5,995$496.16$3MForm 4
Feb 27, 2026Reshma KewalramaniCEOSale plan2,725$490.54$1.3MForm 4
Feb 27, 2026Reshma KewalramaniCEOSale plan949$491.30$466KForm 4
Feb 27, 2026Reshma KewalramaniCEOSale plan2,520$493.29$1.2MForm 4
Feb 27, 2026Reshma KewalramaniCEOSale plan3,498$494.33$1.7MForm 4
Feb 27, 2026Reshma KewalramaniCEOSale plan15,580$495.38$7.7MForm 4
Feb 27, 2026Carmen BozicVice presidentSale plan2,329$480.31$1.1MForm 4
Feb 26, 2026Kristen AmbroseVice presidentSale plan357$483.36$173KForm 4
Feb 25, 2026Ourania TatsisVice presidentSale plan260$486.35$126KForm 4
Feb 25, 2026Amit SachdevVice presidentSale plan1,846$486.35$898KForm 4
Feb 25, 2026Duncan McKechnieVice presidentSale plan2,410$489.00$1.2MForm 4
Feb 25, 2026Duncan McKechnieVice presidentSale plan2,500$486.35$1.2MForm 4
Feb 25, 2026Mark E. BunnageVice presidentSale plan620$486.35$302KForm 4
Feb 25, 2026Jonathan BillerVice presidentSale plan945$486.35$460KForm 4
Feb 25, 2026Edward Morrow Atkinson IIIVice presidentSale plan668$486.35$325KForm 4
Feb 25, 2026Kristen AmbroseVice presidentSale plan223$486.35$108KForm 4
Feb 19, 2026Amit SachdevVice presidentSale plan2,730$465.05$1.3MForm 4
Feb 19, 2026Amit SachdevVice presidentSale plan4,237$471.43$2MForm 4
Feb 19, 2026Amit SachdevVice presidentSale plan920$463.91$427KForm 4
Feb 19, 2026Amit SachdevVice presidentSale plan1,848$465.80$861KForm 4
Feb 19, 2026Amit SachdevVice presidentSale plan10,263$467.75$4.8MForm 4
Feb 19, 2026Amit SachdevVice presidentSale plan19,662$468.57$9.2MForm 4
Feb 19, 2026Amit SachdevVice presidentSale plan7,241$469.61$3.4MForm 4
Feb 19, 2026Amit SachdevVice presidentSale plan11,712$470.54$5.5MForm 4
Feb 18, 2026Ourania TatsisVice presidentSale plan368$473.68$174KForm 4
Feb 18, 2026Mark E. BunnageVice presidentSale plan1,182$473.68$560KForm 4
Feb 18, 2026Jonathan BillerVice presidentSale plan1,244$473.68$589KForm 4
Feb 18, 2026Edward Morrow Atkinson IIIVice presidentSale plan817$473.68$387KForm 4
Feb 18, 2026Kristen AmbroseVice presidentSale plan638$473.68$302KForm 4
Feb 17, 2026Ourania TatsisVice presidentSale plan609$489.46$298KForm 4
Feb 17, 2026Mark E. BunnageVice presidentSale plan2,437$489.46$1.2MForm 4
Feb 17, 2026Jonathan BillerVice presidentSale plan2,476$489.46$1.2MForm 4
Feb 17, 2026Edward Morrow Atkinson IIIVice presidentSale plan2,031$489.46$994KForm 4
Feb 17, 2026Kristen AmbroseVice presidentSale plan1,557$489.46$762KForm 4
Feb 13, 2026Ourania TatsisVice presidentSale plan1,500$499.99$750KForm 4
Feb 13, 2026Jonathan BillerVice presidentSale plan988$499.00$493KForm 4
Feb 13, 2026Sangeeta N. BhatiaDirectorSale plan266$500.00$133KForm 4
Feb 11, 2026Ourania TatsisVice presidentSale plan466$460.43$215KForm 4
Feb 11, 2026Mark E. BunnageVice presidentSale plan2,021$460.43$931KForm 4
Feb 11, 2026Jonathan BillerVice presidentSale plan1,925$460.43$886KForm 4
Feb 11, 2026Edward Morrow Atkinson IIIVice presidentSale plan1,751$460.43$806KForm 4
Feb 11, 2026Kristen AmbroseVice presidentSale plan1,376$460.43$634KForm 4
Jan 7, 2026Ourania TatsisVice presidentSale plan4,500$474.99$2.1MForm 4
Jan 6, 2026Charles F Wagner JrVice presidentSale plan9,532$461.00$4.4MForm 4
Dec 3, 2025Charles F Wagner JrVice presidentSale plan7,000$451.00$3.2MForm 4
Dec 3, 2025Charles F Wagner JrVice presidentSale plan7,000$461.00$3.2MForm 4
Dec 3, 2025Ourania TatsisVice presidentSale plan4,500$449.99$2MForm 4
Dec 3, 2025Jeffrey M LeidenChairSale plan7,899$445.56$3.5MForm 4
Dec 3, 2025Jeffrey M LeidenChairSale plan10,360$453.34$4.7MForm 4
Dec 3, 2025Jeffrey M LeidenChairSale plan15,681$452.20$7.1MForm 4
Dec 3, 2025Jeffrey M LeidenChairSale plan5,809$451.20$2.6MForm 4
Dec 3, 2025Jeffrey M LeidenChairSale plan5,880$449.84$2.6MForm 4
Dec 3, 2025Jeffrey M LeidenChairSale plan2,320$448.78$1MForm 4
Dec 3, 2025Jeffrey M LeidenChairSale plan1,152$447.05$515KForm 4
Dec 3, 2025Jeffrey M LeidenChairSale plan2,070$455.22$942KForm 4
Dec 3, 2025Jeffrey M LeidenChairSale plan4,469$440.40$2MForm 4
Dec 3, 2025Jeffrey M LeidenChairSale plan1,320$441.26$582KForm 4
Dec 3, 2025Jeffrey M LeidenChairSale plan2,469$443.21$1.1MForm 4
Dec 3, 2025Jeffrey M LeidenChairSale plan4,352$444.36$1.9MForm 4
Dec 3, 2025Jonathan BillerVice presidentSale plan347$449.00$156KForm 4
Nov 17, 2025Edward Morrow Atkinson IIIVice presidentSale plan2,500$434.58$1.1MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jeffrey M LeidenExecutive Chairman, Director–$28.7MDec 3, 2025
Amit SachdevEVP Chief Patient & Ext Af Off–$28.4MFeb 25, 2026
Reshma KewalramaniCEO & President, Director–$26MNov 6, 2026
Charles F Wagner JrEVP, CO & FO–$19.2MNov 12, 2026
Carmen BozicEVP and CMO–$11.3MJun 26, 2026
Ourania TatsisEVP, Chief Reg. & Quality Off.–$6.5MJul 2, 2026
Duncan McKechnieEVP, Chief Commercial Officer–$5.7MJul 2, 2026
Jonathan BillerEVP and Chief Legal Officer–$3.8MFeb 25, 2026
Edward Morrow Atkinson IIIEVP, Chief Technical Ops. Off.–$3.6MFeb 25, 2026
Mark E. BunnageEVP, Chief Scientific Officer–$3MMay 15, 2026
Joy LiuEVP and Chief Legal Officer–$2.1MJul 1, 2026
Kristen AmbroseSVP & Chief Accounting Officer–$2MFeb 26, 2026
Sangeeta N. BhatiaDirector–$268KMay 4, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

VRTX short interest

Low short interest. 1.9% of VRTX shares are sold short: about 1 share in 53. Over the last 12 reports the number of shares short went up 8%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 4.81M VRTX shares were sold short, 1.9% of the shares outstanding, up 12.9% from the report before. At the average daily volume of 1.42M shares, buying them all back would take about 3.4 trading days (days to cover).

Shares short, % of all shares

1.90%May 15Oct 302.03%

Days to cover

3.4May 15Oct 305.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20264.81M1.90%+13%1.42M3.4
Oct 15, 20264.26M1.68%-5%1.26M3.4
Sep 30, 20264.50M1.78%-5%1.06M4.2
Sep 15, 20264.72M1.86%+1%938,1575.0
Aug 31, 20264.66M1.84%+12%1.03M4.5
Aug 14, 20264.15M1.64%+5%1.34M3.1
Jul 31, 20263.94M1.56%-21%1.32M3.0
Jul 15, 20264.99M1.96%+1%1.61M3.1
Jun 30, 20264.94M1.95%+7%2.45M2.0
Jun 15, 20264.62M1.82%+3%1.21M3.8
May 29, 20264.49M1.77%+1%1.41M3.2
May 15, 20264.46M1.76%+7%1.22M3.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded VRTX

Since Nov 17, 2024, 5 members of Congress reported 5 purchases and 7 sales of VRTX. The latest was a sale by David J. Taylor on Aug 26, 2026, reported Sep 5, 2026.

Purchases 5Sales 7

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Aug 26, 2026David J. Taylor (R-OH)Sale$1K–$15KSelfSep 5, 2026Report
Mar 27, 2026Alan Armstrong (R-OK)Purchase$1K–$15KSelfJul 21, 2026Report
Jan 29, 2026David J. Taylor (R-OH)Sale$1K–$15KSelfFeb 2, 2026Report
Aug 7, 2025David J. Taylor (R-OH)Purchase$1K–$15KSelfSep 2, 2025Report
Jun 11, 2025Lisa C. McClain (R-MI)Sale$1K–$15KSpouseAug 13, 2025Report
Jun 10, 2025Lisa C. McClain (R-MI)Partial sale$1K–$15KSpouseAug 13, 2025Report
May 12, 2025Jefferson Shreve (R-IN)Sale$15K–$50KSelfJun 22, 2025Report
Mar 20, 2025Byron Donalds (R-FL)Sale$1K–$15KSelfApr 14, 2025Report
Mar 20, 2025Byron Donalds (R-FL)Sale$1K–$15KSpouseApr 14, 2025Report
Mar 13, 2025Jefferson Shreve (R-IN)Purchase$15K–$50KSelfApr 11, 2025Report
Feb 24, 2025Jefferson Shreve (R-IN)Purchase$15K–$50KSelfMar 9, 2025Report
Dec 11, 2024Lisa C. McClain (R-MI)Purchase$1K–$15KSpouseAug 13, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Vertex Pharmaceuticals Inc / Ma company events

Vertex Pharmaceuticals Inc / Ma filed 10 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 2, 2026.

  1. Nov 2, 2026ResultsReleased financial results. Filing
  2. Oct 20, 2026LeadershipDeparture of Directors of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
  3. Sep 1, 2026LeadershipDeparture of Directors of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
  4. Aug 3, 2026ResultsReleased financial results. Filing
  5. Jul 7, 2026AgreementVertex Pharmaceuticals Incorporated, a Massachusetts corporation, Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, and Crinetics Pharmaceuticals, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger. Filing
  6. May 13, 2026LeadershipThe Board of Directors of Vertex Pharmaceuticals Incorporated approved the Vertex Pharmaceuticals Incorporated 2026 Stock and Option Plan, which replaces the Vertex Pharmaceuticals Incorporated 2013 Stock and Option Plan, subject to shareholder approval. Filing
  7. May 4, 2026ResultsReleased financial results. Filing
  8. Apr 29, 2026LeadershipSuketu Upadhyay informed the board of directors of Vertex Pharmaceuticals Incorporated of his decision not to stand for re-election as a director of the Company at the Company’s 2026 annual meeting of shareholders. Filing
  9. Mar 31, 2026AnnouncementVertex Pharmaceuticals Incorporated has completed the submission to the U.S. Food and Drug Administration of its rolling Biologics Licensing Application for potential accelerated approval of povetacicept for the treatment of immunoglobulin A nephropathy in adults. Filing
  10. Feb 12, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

How Vertex Pharmaceuticals Inc / Ma makes money

Trikafta/Kaftrio brought in 86% of Vertex Pharmaceuticals Inc / Ma's revenue ($10.3B of $12B) in 2025. Alyftrek was next, at 7%.

By product or service, 2025

Trikafta/Kaftrio$10.3B · 86%
Alyftrek$838M · 7%
Other medicines$820M · 7%
Journavx$59.6M · 0%
Collaborations and royalties$30.7M · 0%

By region, 2025

United States$7.5B · 63%
Europe$3.5B · 29%
Other Countries Outside of the United States and Europe$992M · 8%

From Vertex Pharmaceuticals Inc / Ma's annual report (10-K) for the year ended Dec 31, 2025, filed Feb 13, 2026. The company chooses how to group its revenue, so the parts differ from one company to the next. Read the filing · How the biggest companies make money

Vertex Pharmaceuticals Inc / Ma financials

Famous investors that hold VRTX

5 of the 50 well-known investors we track reported holding VRTX in their latest 13F filing. The largest position is Ken Griffin's, worth $540M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20261.03M$540M0.3%+102%
Israel Englander · Millennium ManagementQ3 2026567,655$297M0.2%+21%
Jim Simons · Renaissance TechnologiesQ3 2026396,768$207M0.3%+24%
Ray Dalio · Bridgewater AssociatesQ3 202634,915$18.3M0.1%+221%
Ken Fisher · Fisher Asset ManagementQ3 202628,676$15M0.0%+17%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named VRTX in the last 120 days.

FiledHolderFormStake
Nov 13, 2026Capital Research Global Investors13G/A7.0%
Nov 13, 2026Capital Research Global Investors13G/A7.0%

Questions about Vertex Pharmaceuticals Inc / Ma (VRTX) stock

Who owns the most VRTX stock?

The largest reported owner of Vertex Pharmaceuticals Inc / Ma (VRTX) is Capital World Investors, with 10.3% of the company. In total, 1,745 funds and institutions reported holding VRTX at the end of Q2 2026, together about 95% of the shares. See the largest owners.

Are VRTX insiders buying or selling?

In the last 12 months, VRTX insiders reported no open-market purchases and 90 sales worth $140M. The latest trade was on Nov 12, 2026. See every trade.

What is the short interest in VRTX?

As of Oct 30, 2026, 4.81M VRTX shares were sold short, 1.9% of the shares outstanding, up 12.9% from the report before. At the average daily volume of 1.42M shares, buying them all back would take about 3.4 trading days (days to cover). See the history.

Have members of Congress traded VRTX?

Yes. 5 members of Congress reported 5 purchases and 7 sales of VRTX since Nov 17, 2024. The latest was reported on Sep 5, 2026. See the trades.

How does Vertex Pharmaceuticals Inc / Ma make money?

Trikafta/Kaftrio brought in 86% of Vertex Pharmaceuticals Inc / Ma's revenue ($10.3B of $12B) in 2025. Alyftrek was next, at 7%. See the full split.

Which famous investors hold VRTX?

5 of the 50 well-known investors we track reported VRTX in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $540M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.